Dr Reddys Laboratories (RDY) Non-Current Debt (2017 - 2026)

Dr Reddys Laboratories has reported Non-Current Debt over the past 10 years, most recently at $133.5 million for Q1 2026.

  • For Q1 2026, Non-Current Debt rose 46.99% year-over-year to $133.5 million; the TTM value through Mar 2026 reached $133.5 million, up 46.99%, while the annual FY2026 figure was $133.5 million, 45.1% up from the prior year.
  • Non-Current Debt for Q1 2026 was $133.5 million at Dr Reddys Laboratories, up from $90.8 million in the prior quarter.
  • Over five years, Non-Current Debt peaked at $133.5 million in Q1 2026 and troughed at $15.5 million in Q1 2023.
  • A 5-year average of $77.7 million and a median of $76.4 million in 2022 define the central range for Non-Current Debt.
  • Biggest five-year swings in Non-Current Debt: crashed 79.66% in 2023 and later surged 363.95% in 2024.
  • Year by year, Non-Current Debt stood at $76.4 million in 2022, then crashed by 79.66% to $15.5 million in 2023, then surged by 363.95% to $72.1 million in 2024, then increased by 25.9% to $90.8 million in 2025, then skyrocketed by 46.99% to $133.5 million in 2026.
  • Business Quant data shows Non-Current Debt for RDY at $133.5 million in Q1 2026, $90.8 million in Q1 2025, and $72.1 million in Q1 2024.